Martin Allen-Auerbach

About

Martin Allen-Auerbach is a professor in the Pharmacology Department at the University of California, Los Angeles. His clinical research focuses on investigating the role of PET/CT in oncology, particularly its application in improving disease diagnosis, staging, and monitoring of treatment. More recently, he has been involved in researching new PET tracers with an emphasis on non-invasive molecular profiling of neuroendocrine tumors, as well as exploring targeted therapies for neuroendocrine tumors and prostate cancer.

Research topics

• Medicine
• Internal medicine
• Pathology
• Nuclear medicine
• Computer Science
• Oncology
• Urology
• Computer Security
• Political Science
• Emergency medicine

Selected publications

• Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial

  Journal of Nuclear Medicine · 2021 · 128 citations

  PSMA PET/CT and mpMRI have similar accuracy in the detection and intraprostatic localization of prostate cancer foci. mpMRI performs better in identifying EPE and SVI. For the T-staging evaluation of intermediate to high-risk prostate cancer, mpMRI should still be considered the imaging modality of reference. Whenever available, PSMA PET/MRI or the coregistration or fusion of PSMA PET/CT and mpMRI (PSMA PET/CT + mpMRI) should be used as it improves tumor extent delineation.

  PublisherOA PDFDOI

• SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors

  Journal of Nuclear Medicine · 2023 · 108 citations

  The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 18,000 members are physicians, technologists, and scientists specializing

  PublisherOA PDFDOI

• Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences

  Journal of Nuclear Medicine · 2020 · 73 citations

  The COVID-19 pandemic has now reached most countries and is straining health-care systems worldwide to their limits. Emergency room and intensive care staff are at increased risk for infection. Nobody knows the exact mortality rates associated with infections. However, given a likely very large

  DOI

• Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort

  Journal of Nuclear Medicine · 2021 · 46 citations

  Lu-PSMA therapy administration scheme to improve tumor radiation dose delivery and efficacy.

  PublisherOA PDFDOI

• Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)

  Journal of Nuclear Medicine · 2021 · 37 citations

  Lu-PSMA-617 administration schemes (activity levels, time intervals) are needed to optimize tumor dose delivery and treatment efficacy.

  PublisherOA PDFDOI

Frequent coauthors

• Johannes Czernin

  89 shared

• Jérémie Calais

  Molecular Theranostics (United States)

  51 shared

• Ken Herrmann

  45 shared

• Matthias Benz

  Deutschen Konsortium für Translationale Krebsforschung

  37 shared

• Antoni Ribas

  Parker Institute for Cancer Immunotherapy

  30 shared

• Pawan Gupta

  Academy of Scientific and Innovative Research

  30 shared

• Yvonne Y. Chen

  University of California, Los Angeles

  27 shared

• Sven de Vos

  University of California, Los Angeles

  27 shared

Similar researchers at University of California, Los Angeles

• Timothy Cloughesyh-173
• Daniel H. Silvermanh-85